Can pentylenetetrazole and maximal electroshock rodent seizure models quantitatively predict antiepileptic efficacy in Humans?

Seizure

Volumn 24, Issue C, 2015, Pages 21-27

  Yuen, Eunice S M ^a   Trocóniz, Iñaki F ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Drug development; Epilepsy; Maximal electroshock; Pentylenetetrazole; Seizure model; Translational models

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PENTETRAZOLE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ANTICONVULSIVE AGENT; CONVULSANT AGENT;

ALLOMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG EXPOSURE; ELECTRIC SHOCK; HUMAN; MAXIMAL ELECTROSHOCK; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; SEIZURE; SPECIES DIFFERENCE; ANIMAL; BIBLIOGRAPHIC DATABASE; DISEASE MODEL; ELECTROSHOCK; SEIZURES; STATISTICS AND NUMERICAL DATA;

ANIMALS; ANTICONVULSANTS; CONVULSANTS; DATABASES, BIBLIOGRAPHIC; DISEASE MODELS, ANIMAL; ELECTROSHOCK; HUMANS; MICE; PENTYLENETETRAZOLE; RATS; SEIZURES;

EID: 84927738701     PISSN: 10591311     EISSN: 15322688     Source Type: Journal    
DOI: 10.1016/j.seizure.2014.11.006     Document Type: Article

References (135)

1. http://www.ninds.nih.gov/research/asp/index.htm [last accessed 05.08.14].
2. Yuen E, Sims J. How predictive are photosensitive epilepsy models as proof of principle trials for epilepsy? Seizure 2014;23:490-3.
3. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-120.
4. Reith D, Hooper W, Parke J, Charles B. Population pharmacokinetic modelling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinet Pharmacodyn 2001;28:79-92.
5. Messina S, Battino D, Croci D, Mamoli D, Ratti S, Perucca E. Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. Epilepsia 2005;46:372-7.
6. Wright D, Begg E. The 'apparent clearance' of free phenytoin in elderly vs. younger adults. Br J Clin Pharmacol 2010;70:132-8.
7. Xu C, Zou M, Ren J, Tian Y, Yan J, Wang Y, et al. Pharmacokinetics of carbamazepine polymorphs and dihydrate in rats, related to dogs and humans. Arch Pharm Res 2011;34:1973-82.
8. Radulovic L, Turck D, von Hodenberg A, Vollmer K, McNally W, Dehart P, et al. Disposition of gabapentin (Neurontin) in mice, rats, dogs and monkeys. Drug Metab Dispos 1995;23:441-8.
9. Castel-Branco M, Falcao A, Figueiredo I, Caramona M. Lamotrigine pharmaco-kinetic/pharmacodynamics modelling in rats. Fundam Clin Pharmacol 2005;19:669-75.
10. Kapetanovic I, Sweeney D, Rapoport S. Phenobarbital pharmacokinetics in rat as a function of age. Durg Metab Dispos 1982;10:586-9.
11. Jolivette L, Ward K. Extrapolation of human pharmacokinetic parameters from rat, dog and monkey data: molecular properties associated with extrapolative success or failure. J Pharm Sci 2005;94:1467-83.
12. Markowitz G, Kadam S, Boothe D, Irving N, Comi A. The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. Neuroreport 2010;21:452-6.
13. Akula K, Dhir A, Kulkarni S. Effect of various antiepileptic drugs in a pentyl-enetetrazol-induced seizure model in mice. Methods Find Exp Clin Pharmacol 2009;31:423-32.
14. Andres-Mach M, Zokolwska D, Barcicka-Klosowska B, Haratym-Maj A, Florek-Luszczki M, Luszczki J. Effect of ACEA - A selective cannabinoid CB1 receptor agonist on the protective action of different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:301-9.
15. Assi A. N6-cyclohexyladenosine and 3-(2-carboxypiperazine-4-yl)-1-prope-nyl-1-phosphonic acid enhance the effect of antiepileptic drugs against in-duced seizures in mice. J Pharm Pharm Sci 2001;4:42-51.
16. Balakrishnan S, Bhargava V, Pandhi P. Anticonvulsant profile of nimodipine and nitrendipine against pentylenetetrazole induced seizures in rats. Indian J Exp Biol 1999;37:340-3.
17. Beekman M, Ungard J, Gasior M, Carter R, Djikstra D, Goldberg S, et al. Reversal of behavioural effects of pentylenetetrazol by the neuroactive steroid ganax-olone. J Pharmacol Exp Ther 1998;284:868-77.
18. Borowicz K, Luszczki J, Kleinrok Z, Czuczwar S. 7-Nitroindazole, a nitric oxide synthase inhibitor, enhances the anticonvulsive action of ethosuximide and clonazepam against pentylenetetrazole-induced convulsions. J Neural Transm 2000;107:1117-26.
19. Borowicz K, Luszczki J, Czuczwar S. Isobolographic and subthreshold analysis of interactions among felbamate and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice. Epilepsia 2004;45:1176-83.
20. Borowicz K, Piskorska B, Stepniak B, Czuczwar S. Effects of fluoxetine on the anticonvulsant action of valproate and ethosuximide in mouse model of myoclonic convulsions. Ann Agric Environ Med 2012;19:487-90.
21. Cuadrado A, Armijo J. Beneficial interaction between vigabatrin and valproate against seizures induced by pentylenetetrazole in mice. Pharm Res 2005;51:489-96.
22. Dudra-Jastrzebska M, Andres-Mach M, Ratnaraj N, Patsalos P, Czuczwar S, Luszczki J. Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model. Seizure 2009;18:607-14.
23. El-Azab A, ElTahir K. Synthesis and anticonvulsant evaluation of some new 2, 3, 8-trisubstituted-4(3H)-quinazoline derivatives. Bioorg Med Chem Lett 2012;22:327-33.
24. Elmazar M, Hauck R, Nau H. Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid. J Pharm Sci 1992;82:1255-8.
25. Gasior M, Ungard J, Beekman M, Carter R, Witkin J. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazole in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology 2000;39:1184-96.
26. Gravemann U, Volland J, Nau H. Hydroxamic acid and fluorinated derivatives of valproic acid. Anticonvulsant activity, neurotoxicity and teratogenicity. Neurotox Teratol 2008;30:390-4.
27. Kaminski R, Mazurek M, Turski W, Kleinrok Z, Czuczwar S. Amlodipine enhances the activity of antiepileptic drugs against pentylenetetrazole-in-duced seizures. Pharmacol Biochem Behav 2008;68:661-8.
28. Luszczki J, Czuczwar S. Isobolographic profile of interactions between tiaga-bine and gabapentin: a preclinical study. Arch Pharmacol 2004;369:434-46.
29. Luszczki J, Czuczwar S. Isobolographic characterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. Arch Pharmacol 2005;372:41-54.
30. Luszczki J, Ratnaraj N, Patsalos P, Czuczwar S. Pharmacodynamic and/or pharmacokinetic characteristics of interactions between loreclezole and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Epilepsy Behav 2005;7:639-51.
31. Luszczki J, Ratnaraj N, Patsalos P, Czuczwar S. Characterization of the anticon-vulsant, behavioural and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital and valproate using isobolographic analysis. Epilepsia 2006;47:1841-54.
32. Luszczki J, Zuchora M, Sawicka K, Kozinska J, Czuczwar S. Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced sei-zures in mice. Pharmacol Rep 2006;58:658-9.
33. Luszczki J, Szadkowski M, Czuczwar S. Effect of NG-nitro-L-arginine on the anticonvulsant action of four second-generation antiepileptic drugs in pente-trazole-induced clonic seizures in mice. Pharmacol Rep 2007;59:467-73.
34. Luszczki J. Isobolographic analysis of interaction between oxcarbazepine and valproate in pentylenetetrazole-induced seizures in mice. J Preclin Clin Res 2009;2:40-5.
35. Luszczki J, Andres-Mach M, Barcicka-Klosowska B, Florek-Luszczki M, Har-atym-Maj A, Czuczwar S. Effects of WIN 55, 212-2 mesylate (a synthetic cannabinoid) on the protective action of clonazepam, ethosuximide, pheno-barbital and valproate against pentylenetetrazole-induced clonic seizures in mice. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1870-6.
36. Nieoczym D, Socla K, Luszczki J, Czuczwar S, Wlaz P. Influence of sildenafil on the anticonvulsant action of selected antiepileptic drugs against pentylenete-trazole-induced clonic seizures in mice. J Neural Transm 2012;119:923-31.
37. Russo E, Constanti A, Ferreri G, Citraro R, De Sarro G. Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology 2004;46:865-78.
38. Sood Sahai A, Medhi B, Chakrabarti A. Dose-finding study with nicotine as a proconvulsant agent in PTZ-induced seizure model in mice. J Biomed Sci 2008;15:755-65.
39. Thakur A, Sahai A, Thakur J. Experimental re-evaluation of flunarizine as add-on antiepileptic therapy. J Pharm Bioallied Sci 2011;3:253-8.
40. Andurkar S, Stables J, Kohn H. The anticonvulsant activities of N-benzyl 3- methoxypropionamides. Bioorg Med Chem 1999;7:2381-9.
41. Balakrishnan S, Pandhi P, Bhargava V. Effect of nimodipine on the efficacy of commonly used antiepileptic drugs in rats. Indian J Exp Biol 1998;36:51-4.
42. Bialer M, Twyman R, White S. Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav 2004;5:866-72.
43. Borowicz K, Stepien K, Czuczwar S. Fluoxetine enhances the anticonvulsant effects of conventional antiepileptic drugs in maximal electroshock seizures in mice. Pharmacol Rep 2006;58:83-90.
44. Borowicz K, Luszczki J, Sobieszek G, Ratnaraj N, Patsalos P, Czuczwar S. Interactions between zonisamide and conventional antiepileptic drugs in the mouse maximal electroshock test model. Eur Neuropsychopharmacol 2007;17:265-72.
45. Chen J, Sun X, Chai K, Lee J, Song M, Quan Z. Synthesis and anticonvulsant evaluation of 4-(4-alkoxylphenyl)-3-ethyl-4H-1, 2, 4-triazoles as open-chain analogues of 7-alkoxyl-4, 5-dihydro[1, 2, 4]triazolo[4, 3-a]quinolines. Bioorg Med Chem 2007;15:6775-81.
46. Clark C, Sansom R, Lin C, Norris G. Anticonvulsant activity of some 4-amino-benzanilides. J Med Chem 1985;28:1259-62.
47. Czuczwar S, Gasior M, Janusz W, Szczepanik B, Wlodarczyk D, Kleinrok Z. Influence of different methylxanthines on the anticonvulsant action of com-mon antiepileptic drugs in mice. Epilepsia 1990;31:318-23.
48. Deng X, Wei C, Li F, Sun Z, Quan Z. Design and synthesis of 10-alkoxy-5, 6- dihydro-triazolo[4, 3-d]benzo[f][1, 4]oxazepine derivatives with anticonvul-sant activity. Eur J Med Chem 2010;45:3080-6.
49. Fischer W, Bodewei R, Satzinger G. Anticonvulsant and sodium channel blocking effects of ralitoline in different screening models. Arch Pharmacol 1992;346:442-52.
50. Flaherty P, Greenwood T, Manheim A, Wolfe J. Synthesis and evaluation of N- (phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents. J Med Chem 1996;39:1509-13.
51. Garske G, Palmer G, Napier J, Griffith R, Freedman L, Harris E, et al. Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Epilepsy Res 1991;9:161-74.
52. Gasior M, Borowicz K, Buszewicz G, Kelinrok Z, Czuczwar S, et al. Anticonvul-sant activity of phenobarbital and valproate against maximal electroshock in mice during chronic treatment with caffeine and caffeine discontinuation. Epilepsia 1996;37:262-8.
53. Geurts M, Poupaert J, Scriba G, Lambert D. N-(benzyloxycarbonyl)glycine esters and amides as new anticonvulsants. J Med Chem 1998;41:24-30.
54. Guan L, Zhao D, Jiang Z, Piao H, Quan Z. Evaluation of anticonvulsant activity of QUAN-0806 in various murine experimental seizure models. Pharmazie 2009;64:248-51.
55. Guo L, Wei C, Jia J, Zhao L, Quan Z. Design and synthesis of 5-alkoxy- [1, 2, 4]triazolo[4, 3-a]quinoline derivatives with anticonvulsant activity. Eur J Med Chem 2009;44:954-8.
56. Gupta Y, Gupta M, Chaudhary G, Kohli K. Modulation of antiepileptic effect of phenytoin and carbamazepine by melatonin in mice. Methods Find Exp Clin Pharmacol 2004;26:99-102.
57. Lambert D, Vandevoorde S, Diependaele G, Govaerts S, Robert A. Anticonvul-sant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 2001;42:321-7.
58. Leander J. Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anti- convulsant effects of phenytoin, carbamazepine, and ameltolide (LY201116). Epilepsia 1992;33:573-6.
59. Lu Y, Yu R. Synergistic protection of allopregnanolone and phenobarbital against maximal electroshock seizures in mice. Acta Pharmacol Sin 2001;22: 361-4.
60. Lukawski K, Swiderska G, Czuczwar S. Effect of ethacrynic acid on the anti-convulsant activity of the second-generation antiepileptics against maximal electroshock-induced seizures in mice. Epilepsy Res 2009;87:190-6.
61. Lukawski K, Swiderska G, Luszczki J, Czuczwar S. Influence of ethacrynic acid on the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock seizure model. Pharmacol Rep 2010;62:808-13.
62. Lukawski K, Jakubus T, Janowska A, Czuczwar S. Interactions between ACE inhibitors and classical antiepileptic drugs in the mouse maximal electroshock seizures. Pharmacol Biochem Behav 2011;100:152-6.
63. Lukawski K, Swiderska G, Czuczwar S. Effect of hydrochlorothiazide on the anticonvulsant action of antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol Rep 2012;64:315-20.
64. Luszczki J, Trojnar M, Ratnaraj N, Patsalos P, Czuczwar S. Interactions of stiripentol with clobazam and valproate in the mouse maximal electro-shock-induced seizure model. Epilepsy Res 2010;90:188-98.
65. Luszczki J, Czuczwar M, Kis J, Krysa J, Pasztelan I, Swiader M, et al. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003;44:1003-13.
66. Luszczki J, Ratnaraj N, Patsalos P, Czuczwar M. Pharmacodynamic and phar-macokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model. Epilepsia 2005;46:344-55.
67. Luszczki J, Czuczwar M. Gabapentin synergistically interacts with topiramate in the mouse maximal electroshock seizure model: an isobolographic analysis. Pharmacol Rep 2006;58:944-54.
68. Luszczki J, Sacharuk A, Wojciechowska A, Andres-Mach M, Dudra-Jastrzebska. Mohamed M, et al. 7-Nitroindazole enhances dose-dependently the anticon-vulsant activities of conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Pharmacol Rep 2006;58:1734-40.
69. Luszczki J, Sawicka K, Kozinska J, Borowicz K, Czuczwar S. Furosemide potentiates the anticonvulsant action of valproate in the mouse maximal electroshock seizure model. Epilepsy Res 2007;76:66-72.
70. Luszczki J, Czernecki R, Wojtal K, Borowicz K, Czuczwar S. Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maxi-mal electroshock seizure model. J Neural Transm 2008;115:1485-94.
71. Luszczki J, Sawicka K, Kozinska J, Dudra-Jastrzebska D, Czuczwar S. Amiloride enhances the anticonvulsant action of various antiepileptic drugs in the mouse maximal electroshock seizure model. J Neural Transm 2009;116:57-66.
72. Luszczki J, Filip D, Czuczwar S. Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electro-shock-induced seizure model: A type I isobolographic analysis for non-parallel dose-response relationship curves. Epilepsy Res 2010;91:166-75.
73. Luszczki J, Antkiewicz-Michaluk L, Raszewski G, Czuczwar S. Interactions of 1- methyl-1, 2, 3, 4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis. Epilepsy Res 2010;89:207-19.
74. Luszczki J, Misiuta-Krzesinska M, Florek M, Tutka P, Czuczwar S. Synthetic cannabinoid WIN 55, 212-2 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol Biochem Behav 2011;98:261-7.
75. Luszczki J, Borowicz K, Swiader M, Czuczwar S. Interactions between oxcar-bazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003;44:489-99.
76. Luszczki J, Czuczwar S. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 2004;45: 895-907.
77. Luszczki J, Ratnaraj N, Patsalos P, Czuczwar S. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Arch Pharmacol 2006;373:169-81.
78. Luszczki J, Andres M, Czuczwar P, Cioczek-Czuczwar A, Ratnaraj N, Patsalos P, et al. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mousemaximal electroshock seizure model: an isobolographic analysis. Epilepsia 2006;47:10-20.
79. Luszczki J, Antkiewicz-Michaluk L, Czuczwar S. 1-Methyl-1, 2, 3, 4-tetrahydroi-soquinoline enhances the anticonvulsant action of carbamazepine and valpro-ate in the mouse maximal electroshock seizure model. Neuropharmacology 2006;50:133-42.
80. Luszczki J, Czucwar M, Gawlik P, Sawiniec-Pozniak G, Czuczwar K, Sawicka K, et al. Influence of NG-nitro-L-arginine on the anticonvulsant and acute adverse effects of some newer antiepileptic drugs in the maximal electro- shock-induced seizures and chimney test in mice. Pharmacol Rep 2006;58: 955-960.
81. Luszczki J, Czuczwar S. Biphasic characteristic of interactions between stir-ipentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Arch Pharmacol 2006;374:51-64.
82. Luszczki J, Wojda E, Raszewski G, Glowniak K, Cuczwar S. Influence of imperatorin on the anticonvulsant activity and acute adverse-effect profile of lamotrigine in maximal electroshock-induced seizures and chimney test in mice. Pharmacol Rep 2008;60:566-73.
83. Luszczki J, Trojnar MK, Trojnar MP, Kimber-Trojnar Z, Szostakiewicz B, Zadroz-niak A, et al. Effects of amlodipine, diltiazem, and verapamil on the anticon-vulsant action of topiramate against maximal electroshock-induced seizures in mice. Can J Physiol Pharmacol 2008;86:113-21.
84. Luszczki J, Wu J, Raszewski G, Czuczwar S. Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Arch Pharmacol 2009;379:163-79.
85. Marona H, Antkiewicz-Michaluk L. Synthesis and anticonvulsant activity of 1, 2-aminoalkanol derivatives. Acta Poloniae Pharmaceut 1998;55:487-98.
86. Marona H, Szneler E. Preliminary evaluation of anticonvulsant activity of some 4-(benzyloxy)-benzamides. Acta Pol Pharm 2003;60:477-80.
87. Maryanoff B, Costanzo M, Nortey S, Greco M, Shank R, Schupsky J, et al. Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. J Med Chem 1998;41:1315-43.
88. Matagne A, Klitgaard H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res 1998;31:59-71.
89. Mulzac D, Scott K. Profile of anticonvulsant activity and minimal toxicity of methyl 4-[(p-chlorophenyl)amino]-6-methyl-2-oxo-cyclohex-3-en-1-oate and some prototype antiepileptic drugs in mice and rats. Epilepsia 1993;34:1141-6.
90. Nieoczym D, Luszczki J, Czuczwar S, Wlaz P. Effect of sildenafil on the anticonvulsant action of classical and second-generation antiepileptic drugs in maximal electroshock-induced seizures in mice. Epilepsia 2010;51:1552-9.
91. Pandeya S, Singh V, Rupainwar D. Anticonvulsant activity of thioureido derivatives of acetophenone semicarbazone. Pharm Res 1998;37:17-22.
92. Porter R, Cereghino J, Gladding G, Hessie B, Kupferberg H, Scoville B, et al. Antiepileptic drug development program. Cleveland Clin Q 1984;51:293-305.
93. Raju S, Noor A, Gurthu S, Giriyappanavar C, Acharya S, Low H, et al. Effect of fluoxetine on maximal electroshock seizures in mice: acute vs chronic ad-ministration. Pharm Res 1999;39:451-4.
94. Rao V, Rao A, Karanth K. Anticonvulsant and neurotoxicity profile of Nardos-tachys jatamansi in rats. J Ethnopharmacol 2005;102:351-6.
95. Shek E, Murakami T, Nath C, Pop E, Bodor N. Improved anticonvulsant activity of phenytoin by a redox brain delivery system. III: Brain uptake and pharma-cological effects. J Pharm Sci 1989;78:837-43.
96. Shenoy A, Miyahara J, Swinyard E, Kupferberg H. Comparative anticonvulsant activity and neurotoxicity of clobazam, diazepam, phenobarbital, and valpro-ate in mice and rats. Epilepsia 1982;23:399-408.
97. Shindikar A, Khan F, Viwanathan C. Design, synthesis and in vivo anticonvul-sant screening in mice of novel phenylacetamides. Eur J Med Chem 2006;41: 786-792.
98. Stagnitto M, Palmer G, Ordy J, Griffith R, Napier J, Becker C, et al. Preclinical profile of remacemide: a novel anticonvulsant effective against maximal electroshock seizures in mice. Epilepsy Res 1990;7:11-28.
99. Sun X, Wei C, Deng X, Sun Z, Quan Z. Evaluation of the anticonvulsant activity of 6-(4-chlorophenyoxy)-tetrazolo[5, 1-a]phthalazine in various experimental seizure models in mice. Pharmacol Rep 2010;62:273-7.
100. Swiader M, Wielosz M, Czuczwar S. Interaction of astemizole, an H1 receptor antagonist, with conventional antiepileptic drugs in mice. Pharmacol Biochem Behav 2003;76:169-78.
101. Swiader M, Luszczki J, Zwolan A, Wielosz M, Czuczwar S. Effects of some convulsant agents on the protective activity of topiramate against maximal electroshock-induced seizures in mice. Pharmacol Rep 2005;57:373-9.
102. Swinyard E, Wolf H, White S, Skeen G, Stark L, Albertson T, et al. Charac- terisation of the anticonvulsant properties of F-721. Epilepsy Res 1993;15:35-45.
103. Tomczyk T, Haberek G, Zuchora B, Jaroslawska-Zych A, Kowalczyk M, et al. Enhanced glutamatergic transmission reduces the anticonvulsant potential of lamotrigine but not of felbamate against tonic-clonic seizures. Pharmacol Rep 2007;59:462-6.
104. Wlaz P, Rolinksi Z, Kleinrok Z, Czuczwar S. Influence of chronic aminophylline on the anticonvulsant efficacy of phenobarbital and valproate in mice. Epi-lepsia 1993;34:385-9.
105. Zarnowska I, Luszczki J, Zarnowski T, Buszewicz G, Madro R, Cuzczwar S, et al. Pharmacodynamic and pharmacokinetic interactions between common antiepileptic drugs and acetone, the chief anticonvulsant ketone body elevat-ed in the ketogenic diet in mice. Epilepsia 2009;50:1132-40.
106. Zhang L, Guan L, Wei C, Deng X, Quan Z. Synthesis and anticonvulsant activity of some 7-alkoxy-2H-1, 4-benzothiazin-3(4H)-ones and 7-Alkoxy-4H-[1, 2, 4]tria- zolo[4, 3-d]benzo[b][1, 4]thiazines. Chem Pharm Bull 2010;58:326-31.
107. Bailleux V, Vallee L, Nuyts J, Hamoir G, Poupaert J, Stables J, et al. Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2, 6-Dimethylphe-nyl)phthalimide and prototype antiepileptic drugs in mice and rats. Epilepsia 1995;36:559-65.
108. Bailleux V, Vallee L, Nuyts J, Hamoir G, Poupaert J, Stables J, et al. Synthesis and anticonvulsant activity of some 4-nitro-N-phenylbenzamides. Eur J Med Chem 1995;30:1439-44.
109. Clark C. Comparative anticonvulsant activity and neurotoxicity of 4-amino-N- (2, 6-dimethylphenyl)benzamide and prototype antiepileptic drugs in mice and rats. Epilepsia 1998;29:198-203.
110. Loscher W, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res 1991;9:1-10.
111. Dalby N, Nielsen E. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res 1997;28: 63-72.
112. Diouf O, Bourhim M, Lambert D, Poupaert J, Stables J, Vamecq J. Anticonvulsant and neurotoxicological properties of 4-amino-N-(2-ethylphenyl)benzamide, a potent ameltolide analogue. Biomed Pharmacother 1997;51:131-6.
113. Jin H, Sun X, Chai K, Piao H, Quan Z. Anticonvulsant and toxicity evaluation of some 7-alkoxy-4, 5-dihydro-[1, 2, 4]triazolo[4, 3-a]quinoline-1(2H)-ones. Bioorg Med Chem 2006;14:6868-73.
114. Kehne J, Kane M, Chaney S, Hurst G, McCloskey T, Petty M, et al. Preclinical characterization of MDL 27, 192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res 1997;27:41-54.
115. Kruse H, Kuch H. Etifoxine: evaluation of its anticonvulsant profile in mice in comparison with sodium valproate, phenytoin and clobazam. Arzneim-Forsch Drug Res 1985;35:133-5.
116. Luszczki J, Wojcik-Cwilda J, Andres M, Czuczwar S. Pharmacological and behavioral characteristics of interactions between vigabatrin and convention-al antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology 2005;30:958-73.
117. Masereel B, Wouters J, Pochet L, Lambert D. Design, synthesis, and anticon-vulsant activity of 1-(pyrid-3-ylsulfonamido)-2-nitroethylenes. J Med Chem 1998;41:3239-44.
118. Miller A, Wheatley P, Sawyer D, Baxter M, Roth B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia 1986;27:483-9.
119. Obniska J, Chlebek I, Kaminski K. Synthesis and anticonvulsant properties of new mannich bases derived from 3, 3-disubstituted pyrrolidine-2, 5-diones. Part IV. Arch Pharm Chem Life Sci 2012;345:713-22.
120. Piao F, Peng B, Zhang W, Zhang W, Han R. Synthesis and biological evaluation of 9-alkoxy-6, 7-dihydro-5H-benzo[c] [1, 2, 4]triazolo[4, 3-a]azepines as poten-tial anticonvulsant agents. Arzneimittelforschung 2012;62:202-7.
121. Raza M, Alghasham A, Alorainy M, El-Hadiyah T. Potentiation of valproate-induced anticonvulsant response by Nigella sativa seed constituents: the role of GABA receptors. Int J Health Sci 2008;2:15-25.
122. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos E, et al. D- 23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-23.
123. Rowley N, White S. Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: correlation with other seizure and epilepsy models. Epilepsy Res 2010;92:163-9.
124. Shank R, Gardocki G, Vaught J, Davis C, Schupsky J, Raffa R, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
125. Swinyard E, Sofia R, Kupferberg H. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986;27:27-34.
126. Swinyard E, White S, Wolf H, Bondinell W. Anticonvulsant profiles of the potent and orally active GABA uptake inhibitors SK&F 89976-A and SK&F 100330-A and four prototype antiepileptic drugs in mice and rats. Epilepsia 1991;32:569-77.
127. Tantisira B, Tantisira M, Patarapanich C, Sooksawate T, Chunngam T. Prelim-inary evaluation of the anticonvulsant activity of a valproic acid analog: N-(2-propylpentanoyl) urea. Res Comm Mol Pathol Pharmacol 1997;97: 151-63.
128. Ulloque R, Chweh A, Swinyard E. Effects of g-aminobutyric acid (GABA) receptor agonists on the neurotoxicity and anticonvulsant activity of barbi-turates in mice. J Pharmacol Exp Ther 1986;237:488-572.
129. Wei C, Guan L, Jia J, Chai K, Quan Z. Synthesis of 2-substituted-6-(4H-1, 2, 4- triazol-4-yl)benzo[d]oxazoles as potential anticonvulsant agents. Arch Pharm Res 2009;32:23-31.
130. White S, Brown S, Woodhead J, Skeen G, Wolf H. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997;28:167-79.
131. White S, Franklin M, Kupferberg H, Schmutz M, Stables J, Wolf H. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia 2008;49:1213-20.
132. Yamashita H, Ohno K, Amada Y, Hattori H, Ozawa-Funatsu Y, Toya T, et al. Effects of 2-[N-(4-chlorophenyl)-N-methylamino]-4Hpyrido[3.2-e]-1, 3-thia- zin-4-one (YM928), an orally active alpha amino-3-hydroxy-5-methyl-4-iso-xazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats. J Pharmacol Exp Ther 2004;308:127-33.
133. Zelger K, Zelger J, Carlini E. New anticonvulsants derived from 4-allyl-2- methoxyphenol (eugenol): comparison with common antiepileptics in mice. Pharmacology 1983;27:40-9.
134. Dingemanse J, van Bree J, Danhof M. Pharmacokinetic modelling of the anticonvulsant action of phenobarbital in rats. J Pharmacol Exp Ther 1989;249: 601-8.
135. Della Paschoa O, Hoogerkamp A, Edelbroek P, Voskyl R, Danhof M. Pharmaco-kinetic-pharmacodynamic correlation of lamotrigine, flunarizine, loreclezole, CGP40116 and CGP39551 in the cortical stimulation model. Epilepsy Res 2000;40:41-52.